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ABSTRACT 
Objectives: The aim of this study is to evaluate the impact of ovarian endometrioma according to its size on the serum 
anti-Mullerian hormone (AMH) levels compared to that of other benign ovarian cysts. 
Material and methods: The current study retrospectively evaluated preoperative serum AMH level and its association to present-
ing ovarian cyst size which were measured in clinical setting. Women with surgically diagnosed endometrioma or other benign 
ovarian cysts were included. All patients underwent transvaginal or transrectal ultrasonography to determine the size of the 
ovarian cysts. Preoperative serum AMH level was checked and evaluated according to histologic type of the cyst, which were 
endometrioma or other benign ovarian cysts, respectively. Both groups were classified into ≤ 4 cm, > 4 cm and ≤ 8 cm, > 8 cm 
and ≤ 12 cm, > 12 cm according to the diameter of cyst and analyzed the difference of mean AMH levels in both groups.
Results: There was no significant difference in preoperative serum AMH level between the two groups (3.36 ± 2.3 versus 
3.76 ± 2.64, p = 0.331). The difference of preoperative AMH levels  according to categorized cyst size also was not statisti-
cally significant in both groups. 
Conclusions: Preoperative serum AMH levels were not statistically different between endometrioma and other benign 
ovarian cyst groups and were not related to the size of endometrioma. 
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INTRODUCTION 
Anti-Müllerian hormone (AMH) is a dimeric glycoprotein 
that belongs to the transforming growth factor-beta family [1]. 
It is involved in the regression of the Müllerian ducts dur-
ing male fetal development. In the female, AMH is solely 
produced by the granulosa cells of primary, preantral and 
small antral follicles in the ovaries [2]. 
Clinical aspects of AMH have some exclusive character-
istics; the serum AMH level is closely related with age, with 
insignificant intra- and inter-cycle variation throughout 
menstrual cycles [3, 4]. Because of such characteristics, 
AMH has been significantly used in several clinical prac-
tices such as assisted reproductive technologies [5, 6], 
prediction of menopause and diagnosis of PCOS [7–10]. 
Yet, while serum AMH level may be the best marker of 
ovarian reserve, the utility as a predictive marker for live 
births or timing of menopause is not reached to the defi-
nite conclusions [7].
In gynecological perspective with interests in clinical use 
of AMH, the impact of a benign ovarian cyst on physiological 
serum AMH level is also one of the clinical issues with indefi-
nite conclusion [11–13]. Such debate could be considered in 
two points; influence of surgery for an ovarian cyst and that 
of an ovarian cyst itself on the serum AMH level.
Regarding the influence of surgery on ovarian cysts 
and serum AMH level, it is widely accepted that ovarian re-
serve measured with serum AMH level would be reduced 
after ovarian cystectomy [14–16]. Henes et al. reported that 
serum AMH level was significantly decreased after surgery 
on a follicular cyst and endometriosis, but not on dermoid 
and other cysts [15]. 
When considering the influence of endometrioma on the 
serum AMH level, several subordinate concepts are needed 
to be pondered: the stage, laterality and size of endometrio-
ma. Still, conflicting results are being observed; some reports 
have suggested that the serum AMH level is relatively low in 
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the endometrioma group [17, 18], but the opposite findings 
have been also reported [19, 20]. Karadag et al. [17] reported 
lower AMH levels in patients with bilateral endometrioma 
than patients with unilateral endometrioma and lower AMH 
levels in women with deep infiltrating endometriosis. Simi-
larly, Uncu et al. [18] found that endometrioma patients have 
lower AMH levels and antral follicle count when compared 
to the control and suggested that the presence of endome-
trioma itself is associated with a reduction in ovarian reserve. 
On the other hand, Kim et al. [19] suggested that the serum 
AMH level were not different between the endometrioma 
and teratoma groups, but in age-body mass index matched 
stage IV endometriosis, the serum AMH level was lower 
in the endometrioma group. Despite the ongoing debate, 
general consensus is that higher stage and bilaterality of 
endometrioma are more likely to result low AMH [21–23]. 
Expanding the issue to the relationship of size of endo-
metrioma and serum AMH level, the controversies have been 
either insignificant or negative relationship of the two. How-
ever, the recent study of Marcellin et al. [20] has found strik-
ingly positive association between the size of endometrioma 
and serum AMH level, introducing novel understanding of 
physiological characteristics of endometrioma and interpret-
ing the associated AMH level. Currently, valuable scholarly 
investigations on AMH concentrations according to the size of 
endometrioma have been more complicated to be answered. 
The aim of this study is to evaluate the impact of ovar-
ian endometrioma according to its size on the serum an-
ti-Mullerian hormone (AMH) levels compared to that of 
other benign ovarian cysts.
MATERIAL AND METHODS
Patients 
This retrospective study was conducted at Department 
of Obstetrics and Gynecology, Pusan National University 
Hospital. Women with surgically diagnosed endometrioma 
between October 01, 2012 and October 01, 2019 were in-
cluded as the study group. The exclusion criteria were prior 
ovarian surgery, irregular menstrual periods, the presence of 
polycystic ovary syndrome, hyperprolactinemia or abnormal 
thyroid function test (TFT), and medication history with 
dysmenorrhea management such as GnRH analogues, oral 
contraceptives or progestins during the past 3 months to the 
recruitment. The control group was comprised of women 
with benign ovarian cysts other than endometrioma. The 
same exclusion criteria were applied to the controls. BMI was 
calculated as the patient’s weight in kilograms divided by 
her height in meters squared. All patients underwent lapa-
roscopic or laparotomic ovarian cystectomy. All specimens 
obtained intraoperatively were submitted for pathologic 
examination, and pathologic confirmation was done in all 
cases. All patients agreed and provided informed consent 
forms indicating that their medical records were to be used 
for the study. The study was approved by the ethics com-
mittee of Pusan National University Hospital.
Measurement of ovarian cyst size 
All patients underwent transvaginal or transrectal ultra-
sonography to determine the size of the endometriomas or 
other benign ovarian cysts using a 5–9 MHz transvaginal 
transducer or transrectally for virgin patients on the day 
before surgery (Voluson E6 General Electric, Milwaukee, 
Wauwatosa, WI, USA). The cyst size was recorded as the 
average of the largest and shortest diameters in centim-
eters. Each cyst diameters were measured vertically from 
outer-membrane to the opposite outer-membrane. Bilateral 
cysts were recorded as the sum of the two cyst sizes.
Assay of AMH and inflammatory markers
All of women underwent blood sampling for preopera-
tive AMH measurements and inflammatory markers within 
a month prior to surgery. Blood samples were obtained from 
patients after 8hrs of overnight fast, including following 
measurements, using Roche Modular DP (Tokyo, Japan): 
complete blood cell count including number of white blood 
cells (WBC), percentages of segmented_neutrophils and 
lymphocytes and segmented neutrophil/lymphocyte (N/L) 
ratio. Serum AMH assay was performed using an anti-Mul-
lerian hormone/Mullerian inhibiting substance Enzyme 
Immuno Assay (AMH/MIS EIA) kit (Immunotech version, 
Beckman Coulter, Marseille, France). The coefficients of vari-
ation of intra-assay and inter-assay were 12.3% and 14.2%, 
respectively. The distribution of AMH values  for two or three 
days of the physiological cycle according to the patient’s 
age is determined by using 5%, 10%, 25%, 50%, 75%, 90%, 
95%, and mean values  according to age was calculated [24].
Statistics
All statistical data was organized into a computerized 
database. Variables were evaluated for clinical significance 
using chi-square test and Fisher’s exact test for categorical 
variables or the independent t-test for continuous variables, 
where appropriate. One-way ANOVA was used to compare 
preoperative serum AMH levels according to categorized cyst 
sizes in the endometrioma group and control group. Pearson 
correlation coefficient was used for correlation between pre-
operative AMH level, age, ovarian cyst size and inflammatory 
markers. Using multiple linear regression analysis, factors 
affecting preoperative serum AMH level were studied. The 
statistical analysis was performed SPSS version 22.
RESULTS
The mean age of the patients was higher in the endo-
metrioma group compared to the control group, which 
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were 30.45 ± 5.99 years and 28.09 ± 7.55 years, respectively 
(p = 0.034). Parity was lower in the endometrioma group 
than in the control group (0.09 ± 0.35 versus 0.30 ± 0.71, 
p = 0.033) and showed a regular menstrual cycle compared 
to the control group (79.66% vs 20.34%, p < 0.001). In ad-
dition, dysmenorrhea in the endometrioma group were 
higher than the control group (82.2% vs 59.38%, p = 0.001). 
There were no significant differences in preoperative serum 
AMH level between the two groups (3.36 ± 2.3 vs 3.76 ± 2.64, 
p = 0.331). Serum WBC count and N/L ratio were significantly 
higher in endometriosis group than in control group (Tab. 1).
Table 2 shows the difference of preoperative AMH 
levels according to cyst size in endometrioma and con-
trol group. The groups were classified into ≤ 4 cm, > 4 cm 
and ≤ 8 cm, > 8 cm and ≤ 12 cm, > 12 cm according to the 
cyst size. The difference of preoperative AMH levels accord-
Table 1. Basic characteristics of the patients in control and endometrioma group
Overall (n = 182) Control (n = 64) Endometrioma (n = 118) p value
Age 29.62 (6.66) 28.09 (7.55) 30.45 (5.99) 0.034
BMI 21.90 (4.30) 22.51 (4.58) 21.56 (4.12) 0.154
Smoking history* 1.000
Never 175 (96.15) 62 (96.88) 113 (95.76)
Current 7 (3.85) 2 (3.12) 5 (4.24)
Previous 0 (0.00) 0 (0.00) 0 (0.00)
Bilaterality* 0.310
No 128 (70.33) 48 (75) 80 (67.8)
Yes 54 (29.67) 16 (25) 38 (32.2)
Past history* 0.015
None 168 (92.31) 59 (92.19) 109 (92.37)
HTN 3 (1.65) 2 (3.12) 1 (0.85)
DM 1 (0.55) 0 (0.00) 1 (0.85)
Hepatitis 2 (1.1) 2 (3.12) 0 (0.00)
Thyroid disease 7 (3.85) 0 (0.00) 7 (5.93)
Cancer 1 (0.55) 1 (1.56) 0 (0.00)
Gravidity 0.37 (0.86) 0.52 (1.04) 0.30 (0.74) 0.139 
Parity 0.16 (0.51) 0.30 (0.71) 0.09 (0.35) 0.033 
OCs* 1.000
Never 175 (96.15) 62 (96.88) 113 (95.76)
Current 4 (2.2) 1 (1.56) 3 (2.54)
Previous 3 (1.65) 1 (1.56) 2 (1.69)
Menstruation* < 0.001
Regular 129 (70.88) 35 (54.69) 94 (79.66)
Irregular 53 (29.12) 29 (45.31) 24 (20.34)
Dysmenorrhea* 0.001
No 47 (25.82) 26 (40.62) 21 (17.8)
Yes 135 (74.18) 38 (59.38) 97 (82.2)
Menarche 13.32 (1.48) 13.19 (1.61) 13.40 (1.41) 0.381 
AMH (ng/mL) 3.50 (2.63) 3.76 (2.64) 3.36 (2.63) 0.331 
WBC (× 103/uL) 6.66 (2.03) 6.23 (1.56) 6.90 (2.22) 0.019 
Segmented_neutrophil (%) 59.35 (10.65) 58.07 (9.93) 60.05 (11.01) 0.218 
Lymphocyte (%) 31.67 (9.41) 32.83 (8.78) 31.03 (9.71) 0.206 
N/L 2.46 (3.46) 1.99 (0.99) 2.71 (4.22) 0.080 
Cyst size (cm) 6.90 (4.03) 7.59 (4.10) 6.52 (3.96) 0.091 
Data are presented as the means (SD); * values are presented as the number of patient (%); p value by independent t-test for continuous variable; * Chi-square test 
or Fisher’s exact test for categorical variable; BMI — body mass index; HTM — hypertension; DM — diabetes mellitus; OCs — oral contraceptives; AMH — anti-
Mullerian hormone; WBC — white blood cell; N/L — segmented neutrophil/lymphocyte ratio
316
Ginekologia Polska 2020, vol. 91, no. 6
www. journals.viamedica.pl/ginekologia_polska
ing to categorized cyst size was not statistically significant in 
both groups (p = 0.336, p = 0.675, respectively), regardless 
of bilaterality (Fig. 1). 
Table 3 shows the results of the correlation between 
inflammatory markers and preoperative AMH levels. Pear-
son correlation coefficient showed only age factors have 
a significantly negative correlation (Rho value = –0.357 with 
p < 0.0001). Serum WBC count and N/L ratio had Rho values 
of –0.009 (p = 0.907) and –0.022 (p = 0.766), respectively. 
The result of multiple linear regression analysis includ-
ing age, cyst size, serum WBC count and N/L ratio showed 
non-significant statistical correlation except age (coefficient 
β = –0.15, p < 0.0001). 
DISCUSSION
The surgery-related decrease of ovarian reserve in endo-
metriosis is relatively well-established finding [2, 15, 16, 18]. 
However, the impact of ovarian endometrioma itself on 
ovarian reserve — one of the most important preopera-
tive characteristics to decide further treatment method 
— showed inconsistent results. Uncu et al. [18] reported 
that women with endometrioma had lower AMH levels and 
antral follicle count than controls, and Pacchiarotti et al. [25] 
also observed the negative effect of endometriosis on the 
ovarian reserve, especially in cases of severe endometrio-
sis. The possible underlying mechanism suggested by the 
authors was that increased peritoneal macrophages in en-
dometriosis could have caused substantial damage to ovar-
ian tissue and oxidative stress, inducing oocyte degenera-
tion and apoptosis by disturbing the meiotic spindle [25, 26]. 
Yet, in these studies, the control groups comprised women 
of reproductive age who did not have any ovarian cysts [18]. 
Thus, it would be unclear to conclude whether such reduced 
serum AMH level in the endometrioma group was caused 
specifically by endometrioma or generally by the presence 
of cystic lesion on the ovary. When the control group had 
benign ovarian cysts, some studies have reported the insig-
Table 2. Comparisons of serum AMH level according to cyst size in c`ontrol and endometrioma group
Cyst size (cm) ≤ 4 > 4 & ≤ 8 > 8 & ≤ 12 > 12 p value
Overall (n = 182) 41, 3.39 (2.68) 89, 3.62 (2.68) 35, 3.50 (2.47) 15, 3.27 (2.89) 0.948
Control (n = 64) 9, 5.04 (3.75) 34, 3.82 (2.78) 15, 3.11 (1.62) 6, 3.08 (1.50) 0.336
Endometrioma (n =1 16) 32, 2.92 (2.16) 55, 3.49 (2.64) 20, 3.79 (2.97) 9, 3.39 (3.63) 0.675
Data are presented as the number of patients, means (SD)
Table 3. Correlations between preoperative AMH and other 
parameters including all groups
(n = 182) Rho value p value
Age [years] –0.357 < 0.0001
Average of cyst size [cm] –0.051 0.492
N/L ratio –0.022 0.766
Number of WBC –0.009 0.907
AMH — anti-Mullerian hormone; N/L — segmented neutrophil/lymphocyte; 
WBC — white blood cell
Figure 1. The value of the serum AMH according to average 
ovarian cyst size; A. Overall group; B. Control group including benign 
ovarian cyst except endometrioma; C. Endometrioma group
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nificant difference in AMH level between the control and the 
patient group with endometrioma [12, 19]. More detailed 
evaluation and analysis according to the characteristics of 
endometrioma itself and suitable control group are required 
to interpret AMH level in endometrioma patients. 
Recently, Marcellin et al. [20] evaluated serum AMH 
levels in endometrioma patients according to the size of the 
cyst; interestingly, they reported that serum AMH levels in 
women with no prior history of surgery for endometrioma 
increased with the cyst size of endometrioma. In the con-
trol group, non-endometrioma benign ovarian cyst group, 
serum AMH levels was not related with the size of cyst. The 
authors concluded that serum AMH level had positive cor-
relation with endometrioma size and was not affected by 
laterality of endometrioma or deep infiltrating endometrio-
sis, which was strikingly different from previous literature.
In this study, to investigate such inconclusive effect of 
endometrioma itself on serum AMH level according to its 
size, we compared the preoperative AMH level between 
endometrioma and other benign ovarian cyst group, con-
ducting subgroup analysis according to corresponding 
ovarian cyst size. 
First, we observed that the effect of benign ovarian cyst 
on serum AMH level was not different between the endome-
trioma and the other benign ovarian cyst group. Such result 
of ours was in agreement with the study of Streuli I et al. [13], 
in which they reported that the serum AMH levels was not 
different between women with endometriosis and women 
with benign gynecological condition (endometrioma group, 
3.6 ± 3.1 ng/mL and control group, 4.1 ± 3.4 ng/mL, p = 0.06). 
Therefore, preoperative serum AMH level seems to be similar 
between endometrioma and other benign ovarian cysts, as 
previously known [13, 20]. 
Next, we compared the relationship of ovarian cyst size 
and serum AMH level. In our study, there was no statistical 
difference between endometrioma size and serum AMH lev-
el, which was inconsistent with the results of Marcellin et al. 
However, except for the endometrioma with size of more 
than 12 cm, the serum AMH level tended to be increased 
with the increasing cyst size. Additionally, we have run the 
same statistical analysis on unilateral endometrioma and 
bilateral endometrioma separately, and, interesting enough, 
the similar pattern was observed (data not shown). Despite 
statistical insignificance, in unilateral endometrioma, serum 
AMH level tended to be increased with increasing cyst size 
up to 6 cm and dropped thereafter; in bilateral endome-
trioma, the same tendency was observed up to the cyst 
size of 12 cm. At this point, we supposed that serum AMH 
level increased with increasing endometrioma size up to 
a certain limit — in this study, the upper limit was 12 cm in 
diameter when the unilateral and bilateral endometrioma 
were combined — and became insignificant thereafter. 
Though further statistical analysis on subdivided sizes of 
endometrioma is warranted, based on the current results, 
the size of endometrioma might have affected the serum 
AMH level, not necessarily reflecting the ovarian reserve, 
which concurs with the results of Marcellin et al. [20]. 
Marcellin et al. suggested three hypotheses to explain 
their results [20]. First is selection bias. In case of women 
with low AMH levels, surgical management tended to be 
avoided. Second, they suggested that there may be in-
creased secretion of AMH into the circulation by the ovaries 
as the size of the endometrioma increases; inflammation 
and neoangiogenesis in endometriosis could boost the 
local blood clearance from the ovaries. Third, the toxicity 
of endometrioma on the ovarian reserve may contribute 
improved primordial follicular stimulation and consequently 
an increase in serum AMH levels.
Of the three hypotheses of Marcellin et al. [20], regarding 
the selection bias, we also excluded infertile patients, suggest-
ing the potential of selection bias may exist. Streuli et al. [13] 
excluded infertile patients who were more likely to have 
lower basal AMH in their study as well, and they reported 
similar results to ours. Considering the effect of infertile 
patient, Kim et al. [19] reported that the preoperative serum 
AMH was not different between endometrioma and mature 
cystic teratoma, including infertile patients in their subject 
group (endometrioma group 9.8% and control group 7.8%, 
p = not significant, respectively); additionally, in case of 
stage IV endometriosis, the serum AMH level was lower 
in the endometrioma group. Thus, regardless of including 
infertile patient to the subject group, the basal serum AMH 
level was not significantly different between patients with 
endometrioma or other benign ovarian cysts. Still, more 
detailed and larger studies are needed considering infertility 
history and endometrioma severity.
For evaluating the effect of inflammation, we analyzed 
the relationship of inflammation markers; WBC count and 
N/L ratio. The results showed no statistical relevance. How-
ever, it is hard to define that the number of serum WBCs 
and N/L ratio reflected the inflammatory environment of 
peritoneal cavity related with endometrioma. It is neces-
sary to analyze the inflammatory marker of peritoneal fluid.
Last, as reported elsewhere, an increase in endome-
trioma size might cause increasing toxicity on the ovarian re-
serve, and short-term exposure of human ovarian follicles to 
cyclophosphamide metabolites seems to promote follicular 
activation in vitro [27, 28]. However, such studies were con-
ducted in vitro, and the toxicity of cyclophosphamide me-
tabolite and endometrioma might differ in clinical setting. 
The current study has several limitations. First, the num-
ber of patients included in this study was relatively small. 
However, data were collected in a single institute, and all 
patients were firmly diagnosed by laparoscopic surgery. 
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We clearly excluded minimal or mild endometriosis pa-
tients in control group by laparoscopy, leading the consist-
ency of data to be quite valuable. Second, the mean age 
of control group was significantly lower than the endome-
trioma group. Despite the slightly higher mean age, the 
mean AMH of the endometrioma group was comparable 
to the control group. Thus, we could logically conclude 
that the preoperative AMH were not different between the 
endometrioma and control groups. Lastly, since the current 
study is retrospective, all statistical analysis was inevitably 
performed using previously measured data; yet, Marcellin 
et al. [20] adopted the sum of the largest diameters for bi-
lateral ovarian cysts in their study of increasing serum AMH 
level with endometrioma size, when, in previous literature, 
women with bilateral ovarian cysts had been reported to 
have lower serum AMH levels, irrespective of the nature of 
the cyst [12]. In the current study, regardless of bilaterality 
of ovarian cysts, increasing tendency of serum AMH level 
with ovarian cyst size was observed, giving the important 
perspective of relationship between serum AMH level and 
the size of cyst in endometrioma. 
CONCLUSIONS
The preoperative serum AMH levels were not statistically 
different between the endometrioma and other benign 
ovarian cyst groups and were not related to the size of 
endometrioma. Nevertheless, except for the cysts larger 
than 12 cm in diameter, the serum AMH level tended to have 
positive relationship with increasing endometrioma size. 
With further analyses with larger number of patients and 
more suitable inflammatory markers, future findings on the 
association between serum AMH level and endometrioma 
size could innovatively suggest proper interpretation of 
preoperative serum AMH level and clear management direc-
tion for treatment in endometrioma patients. 
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